Skip to main content
SpringerLink
Log in
Book cover

Tuberculosis Control in Migrating Population pp 133–156Cite as

Control of Drug-Resistant TB

  • Chapter
  • First Online:

  • 276 Accesses

Abstract

Drug-resistant TB (DR-TB) refers to the infection of Mtb that is resistant to at least one anti-tuberculosis drug. The occurrence of DR-TB is caused by non-standardized treatment and/or insufficient management of patient with TB. Most of initially treated patient with non DR-TB can be cured by regular treatment of first-line anti-tuberculosis drug for 6 months. But inappropriate medication of anti-tuberculosis drugs (such as intermittent medication or inappropriate dosage) or early retrieval of anti-tuberculosis drug can induce resistance to anti-tuberculosis drug. And Mtb resistant to anti-tuberculosis drug further causes spread of DR-TB. The spread of drug-resistant Mtb in patients with DR-TB is an important way for spread of DR-TB. The prevalence and spread of drug-resistant Mtb present challenges to the global TB control. Especially along with the formation of global village, diversified flowing of populations for business, travelling, and purchase aggravates the prevalence of DR-TB.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: 2006. WHO/HTM/TB/2006.361. Geneva: World Health Organization; 2006.

    Google Scholar 

  2. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2014.11. Geneva: World Health Organization; 2014.

    Google Scholar 

  3. WHO/IUATLD. Global Project on Anti-tuberculosis Drug Resistance Surveillance. Anti-tuberculosis drug resistance in the world. Third report. Geneva: WHO; 2004. p. 343.

    Google Scholar 

  4. Tang SJ, Xu SF, Li L. Drug-resistant tuberculosis. Beijing: People’s Medical Publishing House; 2014. p. 126–287.

    Google Scholar 

  5. Gao Q, Mei J. Spread is the main reason for high incidence of drug-resistant TB in China. Chin J Antituberculosis. 2015;37(11):1091–6.

    Google Scholar 

  6. Wang ZY. Recent development of studies on drug-resistant TB. Inf Infect Dis. 2018;31(1):19–23.

    Google Scholar 

  7. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2018.09. Geneva: World Health Organization; 2018.

    Google Scholar 

  8. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2017.10. Geneva: World Health Organization; 2017.

    Google Scholar 

  9. Ministry of Health, P. R. China. Compiled data on the national epidemiological sampling survey of TB in 1979; 1981.

    Google Scholar 

  10. Ministry of Health, P. R. China. Compiled data on the national epidemiological sampling survey of TB in 1984/1985; 1988.

    Google Scholar 

  11. Ministry of Health, P. R. China. Compiled data on the national epidemiological sampling survey of TB in 1990; 1992.

    Google Scholar 

  12. Ministry of Health, P. R. China. Compiled data on the national epidemiological sampling survey of TB in 2000; 2002.

    Google Scholar 

  13. Ministry of Health, P. R. China. Report on the national epidemiological sampling survey of TB in 2010; 2012.

    Google Scholar 

  14. Gao Q, Mei J. Spread is the main reason for high prevalence of DR-TB in China. Chin J Antituberculosis. 2015;37(11):1091–6.

    Google Scholar 

  15. Gao Q, Yang CG. Recent spread of TB in China and strategies for its control. J Tuberc Lung Health. 2017;6(13):193–8.

    Google Scholar 

  16. Yang HJ. Present tuberculosis control in migrating population. Med Inf. 2014;2014(19):642–3.

    Google Scholar 

  17. Lu W, Fu YY. Sustainable development of drug resistant TB control in China. J Tuberc Lung Health. 2016;5(4):262–6.

    Google Scholar 

  18. Zhou XJ. Drug resistant TB and its treatment strategies. West Med. 2017;29(1):141–4.

    Google Scholar 

  19. Bu QB. Epidemiology of pulmonary TB and its control measures. Healthcare Nutr China. 2015;25(10):58–9.

    Google Scholar 

  20. Kliiman K, Altraja A, Tang SJ, et al. Factors predicting failed treatment for multidrug resistant TB and extensive drug resistant TB. Chin J Tuberc Respir. 2009;32(8):563.

    Google Scholar 

  21. Du JH, Liu JC, Wang AM, et al. Research developments on drug resistant TB and its impact factors. Med Equip China. 2016;2016(s1):144.

    Google Scholar 

  22. Yang HJ. Present TB control in migrating population. Med Inf. 2014;2014(19):42–643.

    Google Scholar 

  23. Zhang T, Xi MX. Evolvement of directly observed treatment for patients with pulmonary TB. Pract Prev Med. 2017;2017(03):382–5.

    Google Scholar 

  24. Zhao YL, Li L, Zhou XH. Diagnosis of tuberculosis: part I. China Med News. 2006;21(10):14–5.

    Google Scholar 

  25. Zhao YL, Shang M. Laboratory diagnosis of tuberculosis in China. Chin J Lab Med. 2007;30(7):725–58.

    CAS  Google Scholar 

  26. Steingart KR, Ng V, Henry M, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006;6(10):664–74.

    PubMed  Google Scholar 

  27. Yang XJ. Acid-fast staining for detection of bacillus: a comparative study. J Qiannan Med Coll Nat. 2008;21(1):6–7.

    Google Scholar 

  28. Alisjahbana B, Van Crevel R, Danusantoso H, et al. Better patient instruction for sputum sampling can improve microscopic tuberculosis diagnosis. Int J Tuberc Lung Dis. 2005;9(7):814–7.

    CAS  PubMed  Google Scholar 

  29. Hirooka T, Higuchi T, Tanaka N, et al. [The value of proper sputum collection instruction in detection of acid-fast bacillus]. Kekkaku. 2004;79(2):33–7.

    Google Scholar 

  30. Guo J, Fan H, Kang M. Laboratory test for rapid detection of Mycobacterium tuberculosis. Int J Lab Med. 2006;27(9):807–8.

    CAS  Google Scholar 

  31. Steingart K R, Schiller I, Horne D J, et al. Xpert(R) MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2014(1):CD009593.

    Google Scholar 

  32. Safianowska A, Walkiewicz R, Nejman-Gryz P, et al. [Diagnostic utility of the molecular assay GenoType MTBC (HAIN Lifesciences, Germany) for identification of tuberculous mycobacteria]. Pneumonol Alergol Pol. 2009;77(6):517–20.

    Google Scholar 

  33. Sun FS, Wu HN, Gu HM. Research developments on control of drug resistant tuberculosis. Med Rev. 2018;2018(1):86–9.

    Google Scholar 

  34. Yang SL, Bu HL, Fan MB. Drug sensitivity test by BACTEC-MGIT 960 and Roche proportional method: a comparative study. Clin Pract. 2015;2015(12):919–21.

    Google Scholar 

  35. Zheng Y, Xia H, Zhao YL. Sensitivity test of Mycobacterium tuberculosis to first-line and second-line anti-tuberculosis drugs by TREK Sensititre MYCOTB. Chin J Antituberculosis. 2015;37(6):597–602.

    Google Scholar 

  36. Li H, Wang SH, Zhu YK. Diagnosis of multidrug-resistant tuberculosis based on two different molecular biological detections for multidrug-resistant genes. Chin J Health Lab Technol. 2015;25(15):2567–9.

    Google Scholar 

  37. Makinen J, Marttila HJ, Marjamaki M, et al. Comparison of two commercially available DNA line probe assays for detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol. 2006;44(2):350–2.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Committee of Infectious Disease Radiology in Branch of Radiology, Chinese Medical Society. Consensus on imaging diagnosis for grading of pulmonary tuberculosis. Electron J Emerg Infect Dis. 2018;3(2):118–27.

    Google Scholar 

  39. Zhang ZX, Ren GY, Tan YC, et al. CT scanning demonstrations of Rifamycin resistant pulmonary tuberculosis. Guide China Med. 2015;13(25):64–5.

    Google Scholar 

  40. Chen GM, Cheng GX, Zhu SQ, et al. CT scanning demonstration of initially treated patients with single drug resistant pulmonary tuberculosis. Electron J Emerg Inf Dis. 2018;3(2):111–4.

    Google Scholar 

  41. Li CH, Lv SX, Wang HQ, et al. CT scanning demonstrations of multidrug resistant pulmonary tuberculosis and their relationship with CD4 cell count. Chin J Antituberculosis. 2017;39(6):597–603.

    Google Scholar 

  42. Wang YX, Chung MJ, Skrahin A, et al. Literature analysis on radiological demonstrations related to multidrug resistant pulmonary tuberculosis. Electron J Emerg Inf Dis. 2018;3(3):244–53.

    Google Scholar 

  43. Yu WY, Tan WG, Zhong FX, et al. Categorization and typing of drug resistant pulmonary tuberculosis and their diagnostic imaging. Electron J Emerg Inf Dis. 2019;4(1):52–6.

    Google Scholar 

  44. Chinese Anti-tuberculosis Society. 2015 Guideline for chemical treatment of drug resistant tuberculosis. Chin J Antituberculosis. 2015;37(5):421–69.

    Google Scholar 

  45. World Health Organization. WHO guideline for treatment of isoniazid resistant tuberculosis: supplement to the WHO guideline for treatment of drug resistant tuberculosis. Geneva: World Health Organization; 2018.

    Google Scholar 

  46. Companion handbook to the 2014 WHO guidelines for the programmatic management of drug resistant tuberculosis. Chin J Antituberculosis. 2015;37(7):800–2.

    Google Scholar 

  47. Aung KJ, Van Deun A, Declercq E, et al. Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis. 2014;18(10):1180–7.

    CAS  PubMed  Google Scholar 

  48. WHO. Rapid communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). Geneva: World Health Organization; 2018.

    Google Scholar 

  49. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis. 2016 update. Geneva: World Health Organization; 2016.

    Google Scholar 

  50. Dai ZC, Xiao DL, Wan LY. The history of anti-tuberculosis in China. Beijing: People’s Medical Publishing House; 2013. p. 58.

    Google Scholar 

  51. World Health Organization. Global tuberculosis report 2014. Geneva: World Health Organization; 2014.

    Google Scholar 

  52. Zhou L, Xue X, Wang F, et al. Implementation of tuberculosis management. Chin J Antituberculosis. 2013;35(2):120–4.

    Google Scholar 

  53. Disease Control Bureau of Health Ministry, Medial Administration Department of Health Ministry, Center for Disease Control, China. Technical guideline for implementation of tuberculosis control planning in China. Beijing: Peking Union Medical College Press; 2009. p. 20.

    Google Scholar 

  54. Chen J, Wang Y, Hu DY. Effects of directly observed treatment on tuberculosis control. Med Foreign Countries: Social Med. 2005;22(4):166–70.

    CAS  Google Scholar 

  55. Huang CY, Song JD, Li GZ, et al. DOTS in management of outpatients with sputum smear positive pulmonary tuberculosis. Popul Health. 2014;8(24):114.

    Google Scholar 

  56. Jiang L. Research developments on compliance of patients with tuberculosis to medication. Inf Infect Dis. 2012;25(1):55–7.

    Google Scholar 

  57. Ma HX, Wang JY. Effects of health education on patients with pulmonary tuberculosis. China Med Innov. 2012;9(13):147–8.

    Google Scholar 

  58. Guo WR. Family based DOT strategy in 155 patients with sputum smear positive tuberculosis. Chin J Antituberculosis. 2010;32(4):202–3.

    Google Scholar 

  59. Wen K, Ma J. Effects of family based DOT strategy on compliance of initially treated patients with sputum smear positive pulmonary tuberculosis. China Med Innov. 2015;12(3):124–6.

    Google Scholar 

  60. Zhu J. On nursing of patients with pulmonary tuberculosis. China Med Innov. 2012;9(1):85–6.

    CAS  Google Scholar 

  61. Xu GB, Liu FY, Feng QM, et al. New strategy on tuberculosis control in rural areas of Guangxi Zhuang autonomous region of China. Chin J Antituberculosis. 2011;45(1):30–5.

    Google Scholar 

  62. Wang YX. Community based DOT strategy in 56 patients with pulmonary tuberculosis. Anhui Med. 2012;16(11):1720–1.

    Google Scholar 

  63. Li JW, Wu WF, Han DL. Comprehensive survey on pulmonary tuberculosis in peasant workers. China Med Innov. 2011;8(2):26–8.

    Google Scholar 

  64. World Health Organization. Public-private mix for DOTS—global progress. Geneva: World Health Organization; 2004. p. 2–9.

    Google Scholar 

  65. Lal SS, Sahu S, Wares F, et al. Intensified scale-up of public-private mix: a systems approach to tuberculosis care and control in India. Int J Tuberc Lung Dis. 2011;15(1):97–104.

    CAS  PubMed  Google Scholar 

  66. Haq Z, Khan W, Scita A. Promoting public-private mix for TB-DOTS: a multi-country study from the WHO Eastern Mediterranean Region. East Mediterr Health J. 2012;18(5):410–6.

    CAS  PubMed  Google Scholar 

  67. Technical Guidance Team of the national epidemiological sampling survey for tuberculosis. Report on 2000 National Epidemiological Sampling Survey on tuberculosis. Chin J Antituberculosis. 2002;24(2):86–96.

    Google Scholar 

  68. Zhu LY, Zhang QY, Zhong CQ, et al. Implementation of PPM-DOTS tuberculosis control program in urban area of Lianyungang, China. J Nanjing Med Univ (Nat Sci). 2008;28(12):1690–3.

    Google Scholar 

  69. Yang HL, Bao CL, Bai LQ, et al. Telephone based DOTS and traditional DOTS in rural areas of Hunan province, China: a comparative study. Chin J Antituberculosis. 2011;33(10):646–50.

    Google Scholar 

  70. Lu F, Xu H, Fu J. Effects of mobile phone text message based DOTS on compliance of patients with pulmonary tuberculosis. Chin J Antituberculosis. 2012;34(10):651–4.

    Google Scholar 

  71. Bao CL, Bai LQ, Tang Y, et al. Effects of telephone based DOTS and traditional DOTS on therapeutic efficacy of pulmonary tuberculosis. Pract Prev Med. 2012;19(12):1803–6.

    Google Scholar 

  72. Xi MX, Qin Q, Zeng YL, et al. Application of internet based collaborative nursing in management of patients with MHD. J Changsha Univ. 2015;29(1):58–61.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Shenzhen Nanshan Center for Chronic Disease Control, Shenzhen, Guangdong, China

    Fan Zhang & Chun-fa Song

  2. Department of Tuberculosis, The Shenzhen Center for Chronic Disease Control, Shenzhen, Guangdong, China

    Wei-ye Yu

  3. Department of Radiology, Beijing You’an Hospital, Capital Medical University, Beijing, China

    Hong-Jun Li

  4. Shenzhen Center for Chronic Disease Control, Shenzhen, Guangdong, China

    Zheng Yang, Le-cai Ji & Qiu-ting Zheng

  5. Department of Radiology, Beijing Ditan Hospital, Capital Medical University, Beijing, China

    Bu-dong Chen

  6. Department of Radiology, The Shenzhen Center for Chronic Disease Control, Shenzhen, Guangdong, China

    Pu-Xuan Lu

  7. The Third People’s Hospital of Shenzhen, Shenzhen, Guangdong, China

    Tao Chen & Guo-fang Deng

Authors
  1. Fan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wei-ye Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hong-Jun Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chun-fa Song
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Zheng Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bu-dong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Pu-Xuan Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Tao Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Guo-fang Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Le-cai Ji
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Qiu-ting Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Tuberculosis, The Shenzhen Center for Chronic Disease Control, Shenzhen, Guangdong, China

    Wei-ye Yu

  2. Department of Radiology, The Shenzhen Center for Chronic Disease Control, Shenzhen, Guangdong, China

    Pu-Xuan Lu

  3. Department of Tuberculosis, The Shenzhen Center for Chronic Disease Control, Shenzhen, Guangdong, China

    Wei-guo Tan

Rights and permissions

Reprints and permissions

Copyright information

© 2020 People's Medical Publishing House, PR of China

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Zhang, F. et al. (2020). Control of Drug-Resistant TB. In: Yu, Wy., Lu, PX., Tan, Wg. (eds) Tuberculosis Control in Migrating Population. Springer, Singapore. https://doi.org/10.1007/978-981-32-9763-0_7

Download citation

  • DOI: https://doi.org/10.1007/978-981-32-9763-0_7

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-32-9762-3

  • Online ISBN: 978-981-32-9763-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation